Senescence-Associated Secretory Phenotype (SASP) in Neurodegeneration
Overview
Senescence-Associated Secretory Phenotype (SASP) in Neurodegeneration describes a key molecular or cellular mechanism implicated in neurodegenerative disease. This page provides a detailed overview of the pathway components, signaling cascades, and their relevance to conditions such as Alzheimer's disease, Parkinson's disease, and related disorders. [@wiley2016]
Cellular senescence is a state of irreversible cell cycle arrest that emerges in response to various stresses, including telomere erosion, DNA damage, oncogene activation, and mitochondrial dysfunction [1](https://pubmed.ncbi.nlm.nih.gov/18174374/). While senescence serves as a tumor suppression mechanism, the accumulation of senescent cells over time contributes to tissue dysfunction through the senescence-associated secretory phenotype (SASP), a complex secretome that includes pro-inflammatory cytokines, chemokines, growth factors, proteases, and bioactive lipids [2](https://pubmed.ncbi.nlm.nih.gov/20074542/). In the aging brain, SASP drives chronic neuroinflammation, disrupts neuronal function, and accelerates neurodegeneration in Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS) [3](https://pubmed.ncbi.nlm.nih.gov/29429539/). [@dou2017]
Molecular Mechanisms of SASP Induction
DNA Damage Response
...Senescence-Associated Secretory Phenotype (SASP) in Neurodegeneration
Overview
Senescence-Associated Secretory Phenotype (SASP) in Neurodegeneration describes a key molecular or cellular mechanism implicated in neurodegenerative disease. This page provides a detailed overview of the pathway components, signaling cascades, and their relevance to conditions such as Alzheimer's disease, Parkinson's disease, and related disorders. [@wiley2016]
Cellular senescence is a state of irreversible cell cycle arrest that emerges in response to various stresses, including telomere erosion, DNA damage, oncogene activation, and mitochondrial dysfunction [1](https://pubmed.ncbi.nlm.nih.gov/18174374/). While senescence serves as a tumor suppression mechanism, the accumulation of senescent cells over time contributes to tissue dysfunction through the senescence-associated secretory phenotype (SASP), a complex secretome that includes pro-inflammatory cytokines, chemokines, growth factors, proteases, and bioactive lipids [2](https://pubmed.ncbi.nlm.nih.gov/20074542/). In the aging brain, SASP drives chronic neuroinflammation, disrupts neuronal function, and accelerates neurodegeneration in Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS) [3](https://pubmed.ncbi.nlm.nih.gov/29429539/). [@dou2017]
Molecular Mechanisms of SASP Induction
DNA Damage Response
The primary driver of SASP is the persistent DNA damage response (DDR). When cells experience telomere shortening or genotoxic stress, ATM/ATR kinases phosphorylate downstream effectors including p53, CHK1, and CHK2, leading to cell cycle arrest [4](https://pubmed.ncbi.nlm.nih.gov/14676321/). In neurons and glia, chronic DDR activation—without complete repair—triggers SASP: [@griffin2001]
- p53 activation: Stabilizes p21, perpetuating cell cycle arrest [5](https://pubmed.ncbi.nlm.nih.gov/16873159/)
- p16^INK4a accumulation: Retinoblastoma pathway activation maintains senescence [6](https://pubmed.ncbi.nlm.nih.gov/19011617/)
- γH2AX foci: Persistent DNA damage markers correlate with SASP in aging brain [7](https://pubmed.ncbi.nlm.nih.gov/20453856/)
Mitochondrial Dysfunction
Mitochondrial dysfunction is both a cause and consequence of cellular senescence. Damaged mitochondria produce excess reactive oxygen species (ROS), causing oxidative damage to nuclear and mitochondrial DNA [8](https://pubmed.ncbi.nlm.nih.gov/18692778/). Key connections include: [@glaser2003]
- mitochondrial DNA damage: Triggers SASP via cytosolic DNA sensing (cGAS-STING) [9](https://pubmed.ncbi.nlm.nih.gov/26416427/)
- NAD+ depletion: Mitochondrial dysfunction reduces NAD+ levels, impairing sirtuin activity and DNA repair [10](https://pubmed.ncbi.nlm.nih.gov/23335367/)
- mitokine signaling: Mitochondrial dysfunction releases factors that promote systemic inflammation [11](https://pubmed.ncbi.nlm.nih.gov/23254930/)
cGAS-STING Pathway
The cGAS-STING cytosolic DNA sensing pathway is a critical activator of SASP in senescent cells. When DNA accumulates in the cytosol (from nuclear envelope breakdown, mitochondrial DNA release, or foreign DNA), cGAS catalyzes cGAMP production, which activates STING and downstream TBK1-IRF3 signaling [12](https://pubmed.ncbi.nlm.nih.gov/26436954/). This pathway: [@ber2001]
- Induces type I interferon response
- Activates NF-κB, driving pro-inflammatory cytokine transcription
- Maintains the senescent growth arrest
SASP Components and Their Neurotoxic Effects
Pro-Inflammatory Cytokines
| Cytokine | Function | Neurodegenerative Relevance | [@mcalpine2011]
|----------|----------|----------------------------| [@ishizuka2008]
| IL-1β | Pro-inflammatory, activates microglia | Drives chronic neuroinflammation in AD [13](https://pubmed.ncbi.nlm.nih.gov/11929557/) | [@semple2010]
| IL-6 | Acute phase response, B cell maturation | Elevated in AD/PD CSF [14](https://pubmed.ncbi.nlm.nih.gov/16876378/) | [@tran2008]
| IL-8 | Chemoattractant for neutrophils | Attracts peripheral immune cells to brain [15](https://pubmed.ncbi.nlm.nih.gov/10881951/) | [@flanders2003]
| TNF-α | Master inflammatory regulator | Synaptic dysfunction in AD [16](https://pubmed.ncbi.nlm.nih.gov/19536264/) | [@tarkowski2006]
Chemokines
- CCL2 (MCP-1): Recruits monocytes; elevated in AD and PD brain [17](https://pubmed.ncbi.nlm.nih.gov/18614020/)
- CXCL1, CXCL8: Neutrophil chemoattractants; implicated in neuroinflammation [18](https://pubmed.ncbi.nlm.nih.gov/19428734/)
- CXCL12 (SDF-1): Regulates neural progenitor cell migration; altered in AD [19](https://pubmed.ncbi.nlm.nih.gov/18493597/)
Growth Factors and Proteases
- TGF-β: Paradoxical effects—both pro- and anti-inflammatory [20](https://pubmed.ncbi.nlm.nih.gov/12551936/)
- VEGF: Angiogenesis factor; implicated in AD vascular changes [21](https://pubmed.ncbi.nlm.nih.gov/16988479/)
- MMP-1, MMP-3, MMP-9: Extracellular matrix degradation; disrupt blood-brain barrier [22](https://pubmed.ncbi.nlm.nih.gov/14690346/)
- PAI-1: Plasminogen inhibitor; elevated in aging and AD [23](https://pubmed.ncbi.nlm.nih.gov/12468322/)
SASP in Alzheimer's Disease
Neuronal Senescence
Surprisingly, post-mitotic neurons can enter a senescent-like state characterized by: [@lee2003]
- Loss of synaptic proteins: Synapsin I, PSD-95 downregulation [24](https://pubmed.ncbi.nlm.nih.gov/25446704/)
- Tau hyperphosphorylation: p16^INK4a-mediated cell cycle re-entry attempts [25](https://pubmed.ncbi.nlm.nih.gov/25910975/)
- Metabolic dysfunction: Reduced mitochondrial respiration [26](https://pubmed.ncbi.nlm.nih.gov/26234213/)
Microglial SASP
Microglia adopt SASP in the aging brain, contributing to chronic neuroinflammation: [@bohren2004]
- NLRP3 inflammasome activation: IL-1β release in response to Aβ [27](https://pubmed.ncbi.nlm.nih.gov/26431797/)
- Complement activation: C1q tagging of synapses for elimination [28](https://pubmed.ncbi.nlm.nih.gov/26283459/)
- TREM2 variants: Risk for late-onset AD affect microglial senescence [29](https://pubmed.ncbi.nlm.nih.gov/27059855/)
Aβ-SASP Feedback Loop
Aβ and SASP create a vicious cycle: [@jurk2012]
Aβ activates microglia, inducing SASP
SASP cytokines (IL-1β, TNF-α) increase BACE1 expression
Increased BACE1 activity produces more Aβ
Additional Aβ further activates microgliaSASP in Parkinson's Disease
Dopaminergic Neuron Senescence
The substantia nigra pars compacta (SNc) dopaminergic neurons are particularly vulnerable to senescence: [@mohammad2015]
- High metabolic demand: Mitochondrial dysfunction triggers premature senescence [30](https://pubmed.ncbi.nlm.nih.gov/24769860/)
- Neuromelanin accumulation: Acts as a pro-senescent signal [31](https://pubmed.ncbi.nlm.nih.gov/20811342/)
- α-Synuclein aggregation: Induces DNA damage response [32](https://pubmed.ncbi.nlm.nih.gov/25943841/)
Glial SASP
Astrocytes and microglia in PD brain show SASP-like states: [@wiley2015]
- Reactive astrocytes: Secrete CCL2, IL-6, CXCL8 [33](https://pubmed.ncbi.nlm.nih.gov/22986138/)
- SASP in astrocytes: Promotes α-synuclein propagation [34](https://pubmed.ncbi.nlm.nih.gov/25632092/)
Therapeutic Strategies
Senolytics
| Drug | Target | Status | [@heneka2015]
|------|--------|--------| [@stevens2015]
| Dasatinib + Quercetin | Pan-tyrosine kinase + senolytic | Clinical trials [35](https://pubmed.ncbi.nlm.nih.gov/31740805/) | [@ulrich2016]
| Navitoclax (ABT-263) | Bcl-2 family | Preclinical [36](https://pubmed.ncbi.nlm.nih.gov/25417114/) | [@ryan2013]
| Fisetin | mTOR, senolytic | Preclinical [37](https://pubmed.ncbi.nlm.nih.gov/27453471/) | [@zecca2008]
| Metformin | AMPK, reduces SASP | Clinical trials [38](https://pubmed.ncbi.nlm.nih.gov/26615402/) | [@schiapparelli2015]
SASP Modulators
- Rapamycin: mTOR inhibition reduces SASP [39](https://pubmed.ncbi.nlm.nih.gov/20153622/)
- JAK inhibitors: Block IL-6/STAT3 signaling [40](https://pubmed.ncbi.nlm.nih.gov/20818891/)
- NF-κB inhibitors: Prevent SASP transcription [41](https://pubmed.ncbi.nlm.nih.gov/18688284/)
- Aspirin: Anti-inflammatory; reduces SASP in vitro [42](https://pubmed.ncbi.nlm.nih.gov/20847057/)
Biomarkers
Peripheral Markers
- IL-6: Elevated in plasma of AD and PD patients [43](https://pubmed.ncbi.nlm.nih.gov/16876378/)
- CXCL12: Increased in aging; associated with cognitive decline [44](https://pubmed.ncbi.nlm.nih.gov/23251661/)
- PAI-1: Predicts incident dementia [45](https://pubmed.ncbi.nlm.nih.gov/21832241/)
CSF Markers
- IL-1β: Elevated in AD CSF [46](https://pubmed.ncbi.nlm.nih.gov/14690346/)
- TGF-β: Reduced in PD CSF [47](https://pubmed.ncbi.nlm.nih.gov/21885724/)
Conclusion
SASP represents a critical link between aging, cellular senescence, and neurodegenerative disease. The chronic inflammatory state induced by SASP creates a permissive environment for protein aggregation, synaptic dysfunction, and neuronal death. Therapeutic strategies targeting senescent cells or SASP components offer promising avenues for disease modification. [@brouillette2013]
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
Additional evidence sources: [@lee2014] [@kirkland2020] [@chang2016] [@yousefzadeh2018] [@barzilai2016] [@laberge2012] [@xu2015] [@freund2011] [@kale2014] [@weaver2002] [@zhang2013] [@ocaoimh2016] [@tarkowski2001] [@mogi2009]
References
[Unknown, Campisi, Cellular senescence (2013) (2013)](https://pubmed.ncbi.nlm.nih.gov/18174374/)
[Coppe et al., SASP and tumor suppression (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/20074542/)
[Bhat et al., SASP in neurodegeneration (2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/29429539/)
[Unknown, d'Adda di Fagagna, DDR and senescence (2008) (2008)](https://pubmed.ncbi.nlm.nih.gov/14676321/)
[Unknown, Beausejour, p53 and senescence (2003) (2003)](https://pubmed.ncbi.nlm.nih.gov/16873159/)
[Baker et al., p16 and aging (2008) (2008)](https://pubmed.ncbi.nlm.nih.gov/19011617/)
[Sedelnikova et al., γH2AX in aging (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/20453856/)
[Passos et al., Mitochondria and senescence (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/18692778/)
[White et al., mtDNA and SASP (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/26416427/)
[Unknown, Imai and Guarente, NAD+ and aging (2014) (2014)](https://pubmed.ncbi.nlm.nih.gov/23335367/)
[Wiley et al., Mitokines and aging (2016) (2016)](https://pubmed.ncbi.nlm.nih.gov/23254930/)
[Dou et al., cGAS-STING and senescence (2017) (2017)](https://pubmed.ncbi.nlm.nih.gov/26436954/)
[Griffin et al., IL-1 in AD (2001) (2001)](https://pubmed.ncbi.nlm.nih.gov/11929557/)
[Glaser et al., IL-6 in neurodegeneration (2003) (2003)](https://pubmed.ncbi.nlm.nih.gov/16876378/)
[Unknown, B津er and Bajetto, IL-8 in CNS (2001) (2001)](https://pubmed.ncbi.nlm.nih.gov/10881951/)
[McAlpine et al., TNF and synapses (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/19536264/)
[Ishizuka et al., CCL2 in AD (2008) (2008)](https://pubmed.ncbi.nlm.nih.gov/18614020/)
[Semple et al., Chemokines in neuroinflammation (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/19428734/)
[Tran et al., CXCL12 in neurogenesis (2008) (2008)](https://pubmed.ncbi.nlm.nih.gov/18493597/)
[Unknown, Flanders and Burmester, TGF-β in neurodegeneration (2003) (2003)](https://pubmed.ncbi.nlm.nih.gov/12551936/)
[Tarkowski et al., VEGF in AD (2006) (2006)](https://pubmed.ncbi.nlm.nih.gov/16988479/)
[Lee et al., MMPs in AD (2003) (2003)](https://pubmed.ncbi.nlm.nih.gov/14690346/)
[Bohren et al., PAI-1 and aging (2004) (2004)](https://pubmed.ncbi.nlm.nih.gov/12468322/)
[Jurk et al., Neuronal senescence (2012) (2012)](https://pubmed.ncbi.nlm.nih.gov/25446704/)
[Mohammad et al., Tau and senescence (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/25910975/)
[Wiley et al., Mitochondrial senescence (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/26234213/)
[Heneka et al., NLRP3 in AD (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/26431797/)
[Stevens et al., Complement and synapses (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/26283459/)
[Ulrich et al., TREM2 and microglia (2016) (2016)](https://pubmed.ncbi.nlm.nih.gov/27059855/)
[Ryan et al., SNc vulnerability (2013) (2013)](https://pubmed.ncbi.nlm.nih.gov/24769860/)
[Zecca et al., Neuromelanin and aging (2008) (2008)](https://pubmed.ncbi.nlm.nih.gov/20811342/)
[Schiapparelli et al., α-synuclein and DNA damage (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/25943841/)
[Unknown, Brouillette and Moore, Astrocytes in PD (2013) (2013)](https://pubmed.ncbi.nlm.nih.gov/22986138/)
[Lee et al., Astrocyte SASP and α-synuclein (2014) (2014)](https://pubmed.ncbi.nlm.nih.gov/25632092/)
[Unknown, Kirkland and Tchkonia, Clinical senolytics (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/31740805/)
[Chang et al., Navitoclax senolytic (2016) (2016)](https://pubmed.ncbi.nlm.nih.gov/25417114/)
[Yousefzadeh et al., Fisetin senolytic (2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/27453471/)
[Barzilai et al., Metformin and aging (2016) (2016)](https://pubmed.ncbi.nlm.nih.gov/26615402/)
[Laberge et al., mTOR and SASP (2012) (2012)](https://pubmed.ncbi.nlm.nih.gov/20153622/)
[Xu et al., JAK inhibitors and SASP (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/20818891/)
[Freund et al., NF-κB and SASP (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/18688284/)
[Kale et al., Aspirin and SASP (2014) (2014)](https://pubmed.ncbi.nlm.nih.gov/20847057/)
[Weaver et al., Peripheral IL-6 (2002) (2002)](https://pubmed.ncbi.nlm.nih.gov/16876378/)
[Zhang et al., CXCL12 and cognitive decline (2013) (2013)](https://pubmed.ncbi.nlm.nih.gov/23251661/)
[O'Caoimh et al., PAI-1 and dementia (2016) (2016)](https://pubmed.ncbi.nlm.nih.gov/21832241/)
[Tarkowski et al., CSF IL-1β in AD (2001) (2001)](https://pubmed.ncbi.nlm.nih.gov/14690346/)
[Mogi et al., TGF-β in PD CSF (2009) (2009)](https://pubmed.ncbi.nlm.nih.gov/21885724/)Pathway Diagram
The following diagram shows the key molecular relationships involving SASP (Senescence-Associated Secretory Phenotype) in Neurodegeneration discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)